Guggenheim assumed coverage on shares of Tenax Therapeutics (NASDAQ:TENX – Free Report) in a report issued on Monday morning, Marketbeat reports. The brokerage issued a buy rating and a $16.00 target price on the specialty pharmaceutical company’s stock.
Several other equities research analysts have also recently issued reports on the company. William Blair initiated coverage on Tenax Therapeutics in a research note on Monday, September 30th. They set an outperform rating for the company. StockNews.com initiated coverage on Tenax Therapeutics in a research report on Thursday, September 26th. They set a sell rating for the company.
Get Our Latest Research Report on TENX
Tenax Therapeutics Stock Up 12.4 %
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last posted its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.99) by $0.16. As a group, equities analysts forecast that Tenax Therapeutics will post -6.75 earnings per share for the current fiscal year.
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
See Also
- Five stocks we like better than Tenax Therapeutics
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- What is Forex and How Does it Work?
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.